Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity
- PMID: 12967138
- DOI: 10.1097/00130404-200307000-00010
Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity
Abstract
Purpose: Ribonucleotide reductase is the rate-limiting enzyme in the de novo synthesis of deoxyribonucleotide triphosphates, which are utilized in both DNA synthesis and DNA repair. We reported previously that RR enzyme activity and R2 (catalytic subunit of RR) protein levels were increased after exposure to ionizing radiation (IR) in growth-arrested human tumor cells, suggesting that R2 protein expression regulates RR activity to allow for IR damage repair. Using isogenic human nasopharyngeal carcinoma cells in this study, we examine the relationship of overexpression of either the R1 regulatory subunit or the R2 catalytic subunit of RR to the cellular response of IR damage.
Materials and methods: We used three isogenic human nasopharyngeal cancer cell lines previously derived by Zhou et al, including KB, the parental tumor cell line; KB/M1, an R1 protein-overexpressing clone stably transfected with human R1 complementary DNA; and KB/M2, a R2 protein-overexpressing clone stably transfected with human R2 complementary DNA. We initially characterized these isogenic human tumor cell lines in exponential growth for R2 protein expression, RR enzyme activity, and R2 protein changes during the cell cycle by flow cytometry. Subsequently, the IR response in these cell lines was determined by clonogenic survival, cell cycle changes occurring after IR, and an analysis of IR DNA damage determined by pulsed field gel electrophoresis. The effect of combining IR and hydroxyurea, a RR (R2) inhibitor, was also studied in KB and KB/M2 cells.
Results: KB/M2 cells were found to have 4.5-fold higher R2 protein expression and a threefold higher RR enzyme activity in exponential growth than KB and KB/M1. Although R2 protein levels increased at the G1/S transition in all cell lines, KB/M2 cells also demonstrated consistently higher R2 protein levels throughout the cell cycle. Using a linear-quadratic analysis of IR clonogenic survival data, KB/M2 cells were more radioresistant than KB and KB/M1 cells, including both decreased alpha and decreased beta values, a finding that correlates with increased reparable IR damage. KB/M2 cells also show a reduced G2 cell cycle arrest and fewer DNA double strand breaks 18 hours after IR (6 Gy). Exposure of KB/M2 cells to hydroxyurea (300 microM) after exposure to IR restored in vitro radiosensitivity in a manner similar to that found in KB and KB/M1 cells.
Discussion: An increase in R2 protein levels and RR activity in KB/M2 cells results in IR resistance, which appears mediated by enhanced IR damage repair during G2. R1 protein overexpression in these isogenic human tumor cells (KB/M1) did not affect RR activity or IR response.
Comment in
-
Revisiting ribonucleotide reductase as a target to enhance radiation and chemotherapy anti-tumor activity.Cancer J. 2003 Jul-Aug;9(4):247-50. doi: 10.1097/00130404-200307000-00006. Cancer J. 2003. PMID: 12967134 No abstract available.
Similar articles
-
Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.Cancer Res. 1995 Mar 15;55(6):1328-33. Cancer Res. 1995. PMID: 7882331
-
Revisiting ribonucleotide reductase as a target to enhance radiation and chemotherapy anti-tumor activity.Cancer J. 2003 Jul-Aug;9(4):247-50. doi: 10.1097/00130404-200307000-00006. Cancer J. 2003. PMID: 12967134 No abstract available.
-
Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells.Cancer Res. 1998 May 15;58(10):2245-52. Cancer Res. 1998. PMID: 9605773
-
Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.Biomed Pharmacother. 2021 Jan;133:110996. doi: 10.1016/j.biopha.2020.110996. Epub 2020 Nov 20. Biomed Pharmacother. 2021. PMID: 33227712 Review.
-
Signal transduction inhibitors as radiosensitizers.Curr Med Chem Anticancer Agents. 2002 Nov;2(6):727-42. doi: 10.2174/1568011023353651. Curr Med Chem Anticancer Agents. 2002. PMID: 12678723 Review.
Cited by
-
Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization.Front Oncol. 2012 Jan 4;1:56. doi: 10.3389/fonc.2011.00056. eCollection 2011. Front Oncol. 2012. PMID: 22655252 Free PMC article.
-
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network.Cancer Res Commun. 2024 Jul 1;4(7):1863-1880. doi: 10.1158/2767-9764.CRC-23-0370. Cancer Res Commun. 2024. PMID: 38957115 Free PMC article.
-
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.PLoS One. 2013;8(1):e53436. doi: 10.1371/journal.pone.0053436. Epub 2013 Jan 15. PLoS One. 2013. PMID: 23335963 Free PMC article.
-
Folate system correlations in DNA microarray data.BMC Cancer. 2005 Aug 4;5:95. doi: 10.1186/1471-2407-5-95. BMC Cancer. 2005. PMID: 16080796 Free PMC article.
-
Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.Radiat Res. 2010 Nov;174(5):574-81. doi: 10.1667/RR2273.1. Epub 2010 Sep 10. Radiat Res. 2010. PMID: 20954859 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources